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Background: Type 2 diabetes (T2D) increases the risk of many types of cancer. Dysregulation of proteasome-
related protein degradation leads to tumorigenesis, while Exendin-4, a glucagon-like peptide 1 receptor
(GLP-1R) agonist, possesses anti-cancer effects.
Methods: We explored the co-expression of proteasome alpha 2 subunit (PSMA2) and GLP-1R in the Cancer
Genome Atlas (TCGA) database and human cervical cancer specimens, supplemented by in vivo and in vitro
studies using multiple cervical cancer cell lines.
Findings: PSMA2 expression was increased in 12 cancer types in TCGA database and cervical cancer specimens
from patients with T2D (T2D vs non-T2D: 3.22 (95% confidence interval CI: 1.38, 5.05) vs 1.00 (0.66, 1.34) fold
change, P = 0.01). psma2-shRNA decreased cell proliferation in vitro, and tumour volume and Ki67 expression
in vivo. Exendin-4 decreased psma2 expression, tumour volume and Ki67 expression in vivo. There was no
change in GLP-1R expression in 12 cancer types in TCGA database. However, GLP-1R expression (T2D vs non-
T2D: 5.49 (3.0, 8.1) vs 1.00 (0.5, 1.5) fold change, P < 0.001) was increased and positively correlated with
PSMA2 expression in T2D-related (r = 0.68) but not in non-T2D-related cervical cancer specimens. This cor-
relation was corroborated by in vitro experiments where silencing glp-1r decreased psma2 expression. Exen-
din-4 attenuated phospho-p65 and -IkB expression in the NF-kB pathway.
Interpretation: PSMA2 and GLP-1R expression in T2D-related cervical cancer specimens was increased and
positively correlated, suggesting hyperglycaemia might promote cancer growth by increasing PSMA2 expres-
sion which could be attenuated by Exendin-4.
Funding: This project was supported by Postdoctoral Fellowship Scheme, Direct Grant, Diabetes Research and
Education Fund from the Chinese University of Hong Kong (CUHK)
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Diabetes increases the risk of many cancer types and cancer-
related death, particularly in liver, pancreas, colorectal cancer, and
lung cancer [1]. In patients with type 2 diabetes (T2D), a 1% increase
in HbA1C is associated with 1.18-fold increased risk of cancer [2,3].
Research in context
Evidence before this study
Diabetes increases the risk of cancer and cancer-related death.
Inflammation is common in cancer and diabetes, especially for
virus infection-induced cancer, e.g., human papillomavirus
(HPV)-16 and -18 related cervical cancer. The ubiquitin-protea-
some system is responsible for protein homeostasis, which is
disrupted in carcinogenesis. Exendin-4 has been shown to
attenuate cancer growth in prostate, pancreatic, and breast can-
cer. We previously reported the attenuating effect of Exendin-4
on tumour growth in db/db mice induced by mouse epithelial
cervical cancer cells (CUP-1, The Chinese University of human
Papilloma virus-1).
Added value of this study
We demonstrated the proto-oncogenic role of PSMA2 in cervi-
cal cancer specimens from patients with T2D with corrobora-
tive evidence from cellular and animal models. Importantly, we
discovered the increased co-expression of GLP-1R and PSMA2
in human and experimental models of cervical cancer, pro-
moted by hyperglycemia but attenuated by Exendin-4.
Implications of all of the available evidence
Since proteasome inhibitors and GLP-1 mimetics are in clinical
use, our data have strong translational potential. Given the
increased co-expression of GLP-1R and PSMA2 in cervical cancer
and the proto-oncogenic role of PSMA2, GLP-1R agonist might
have the potential to treat cancer especially in patients with
T2D.
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anal cancers due to infection of human papillomavirus (HPV)-16 and
-18 [4], are not uncommon in T2D. Inflammation, often associated
with low-grade chronic infection, plays an important role in carcino-
genesis. As such, the co-existence of diabetes and virus infection may
create an inflammatory microenvironment to promote cancer cell
growth [2,5]. Moreover, T2D is associated with poor survival in
patients with cervical cancer, making T2D an important prognostic
factor for cervical cancer [6].
Genetic mutations, chemical irritation, irradiation, toxins, bacte-
ria, and virus infections are amongst the common causes of tumori-
genesis [7,8]. Cancer is characterized by perturbation of cell growth
and proliferation. The uncontrolled cell proliferation is supported by
high protein turnover in cancer cells. The ubiquitin-proteasome sys-
tem is essential for the maintenance of cellular protein homeostasis,
i.e. the balance between normal protein synthesis and protein degra-
dation [9]. An abnormal protein is first tagged by ubiquitin for its
transfer to the cylinder-like structure of the proteasome complex
with alpha and beta subunits for degradation into small peptides
[10]. Increased proteasome expression or activity may contribute to
carcinogenesis by promoting robust protein turnover [11]. Inhibition
of the proteasome results in cell-cycle arrest and apoptosis, and is a
target for anticancer therapy [12]. Recently, a proteasome gene,
namely PSMA2, has been identified to promote breast cancer cell
growth, indicative of its potential proto-oncogenic role in cancer
[13]. A single nucleotide polymorphism (SNPs) c.328C>G, contribut-
ing to missense protein-coding in PSMA2, has been implicated in
human breast and colorectal cancer [14,15].
In clinical practice, proteasome inhibitors, such as bortezomib and
carfilzomib, are antitumor drugs approved for the treatment of multi-
ple myeloma and lymphoma [16]. The inhibitor-kB (IkB)-nuclear fac-
tor-kB (NF-kB) pathway promotes inflammation which can lead toabnormal cell growth. Increased expression of proteasome can
degrade IkB and release NF-kB with nuclear translocation to activate
transcription of the inflammatory cytokines and cell signals. By
blocking IkB degradation, proteasome inhibitors can prevent nuclear
translocation of NF-kB and inhibit tumour growth [7].
GLP-1 is an incretin hormone released from the L cells in the
lower intestine. It can augment insulin release during meal-time and
suppress glucagon production [17]. Glucagon-like peptide 1 mimetics
include GLP-1 receptor agonist, such as Exendin-4 which binds with
GLP-1R, and dipeptidyl peptidase 4 [DPP-4] inhibitor which inhibits
the degradation of GLP-1. These new classes of blood glucose-lower-
ing drugs carry a low risk of hypoglycaemia with weight-neutral or
weight-reducing effects [18,19].
There are emerging reports on the anti-cancer effects of GLP-1
mimetics although the mechanisms require further elucidation.
Exendin-4 has been shown to attenuate the proliferation of human
prostate cancer cells through inhibition of extracellular signal-regu-
lated kinase (ERK)-mitogen-activated protein kinase (MAPK) [20]. In
patients with prostate cancer, Exendin-4 enhanced the responsive-
ness to chemotherapy and reduced cancer growth by activating the
phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR (the mammalian tar-
get of rapamycin) pathways [21]. In human pancreatic and breast
cancer cell lines, GLP-1R agonist, liraglutide, attenuated cancer
growth by inhibiting cellular proliferation and inducing apoptosis
through inhibition of the NF-kB pathway [22,23]. In a meta-analysis
of randomized controlled trials (RCTs) involving 63,594 patients with
T2D, subgroup analyses indicated that treatment with albiglutide, a
GLP-1 agonist, was associated with 24% (95% confidence interval (CI)
0.60-0.97) reduction of all-site cancer compared with the placebo
group. However, the number of cancer cases was only 91 in the treat-
ment group and 119 in the placebo group [24].
In experimental studies, GLP-1 has been shown to exert anti-
inflammatory effects in multiple organs, including the heart, brain,
kidney, liver, pancreas, skin, and testis [25]. This effect was in part
mediated by suppressing the immune system such as macrophages,
dendritic cells, and mast cells with reduced release of pro-inflamma-
tory cytokines (e.g., interleukin (IL)-1b, IL-6, IL-12), nitric oxide (NO),
and tumour necrosis factor (TNF)-a [26]. In this light, our group has
reported the ex vivo inhibitory effects of Exendin-4 on the release of
cytokines from peripheral blood mononuclear cells extracted from
patients with T2D [27].
Using the Hong Kong Diabetes Register established since 1995,
our group was amongst the first to report the high incidence of can-
cer in Chinese patients with T2D, which was closely associated with
glycaemia [28,29]. These epidemiological studies have motivated our
group to develop the CUP-1 epithelial cancer cell line to explore the
mechanisms of this diabetes-cancer link. The CUP-1 is an immortal
mouse epithelial cancer cell line generated from the kidney of baby
C57BL/6J mice with the insertion of the HPV-16 E7 oncogene [30].
We established a diabetes/cancer model by subcutaneous inoculation
of CUP-1 cancer cells in the diabetic db/db mice, followed by tumour
growth to a maximum volume by day 14. Compared with vehicle,
Exendin-4 attenuated the tumour growth [31] although the underly-
ing mechanism remains unknown.
Both cancer and T2D are characterized by excessive protein turn-
over. Given the importance of proteasome in protein homeostasis,
we interrogated TCGA database and noted increased expression of
PSMA2 in 12 cancer types based on human samples, including cervi-
cal cancer. Supported by these clinical findings, we explored the
effect of high glucose on PSMA2 expression in cervical cancer includ-
ing human, in vivo, and in vitro systems. To further explore the anti-
tumour effects of Exendin-4 reported in our previous experiment
[31], we examined the expression of GLP-1R and the effect of Exen-
din-4 on psma2 expression and tumour growth and associated
changes in the NF-kB pathway using cellular, animal and human
samples.
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cervical cancer from patients with T2D. Secondly, PSMA2-O/E and
-shRNA increased and decreased cell proliferation under high glucose
condition and tumour volume in db/db mice, respectively. Thirdly,
high glucose increased GLP-1R expression in vitro and Exendin-4
reduced PSMA2 expression, decreased cell proliferation, and attenu-
ated tumour volume. Lastly, GLP-1R expression was increased in cer-
vical cancer specimens from patients with T2D.
We used complementary human specimens, in vivo, and in
vitro models to test these hypotheses. We first examined PSMA2
expression in cervical cancer specimens from patients with T2D, fol-
lowed by human and mouse cervical cancer cell lines. Secondly, we
generated stable cell lines with psma2-O/E or -shRNA transfection in
CUP-1 cells to explore the role of psma2 in cell proliferation and
tumour growth. Thirdly, we examined the effect of Exendin-4 on
psma2 expression, cell proliferation, and tumour growth. Fourthly,
we examined GLP-1R expression and its correlation with PSMA2
expression in cervical cancer specimen from patients with T2D, fol-
lowed by confirmation from cervical cancer cell lines. Lastly, we
explored the effects of high glucose and Exendin-4 on the NF-kB
pathway, including phospho-p65 and phospho-IkB levels.2. Methods
2.1. Pan-cancer expression of PSMA2 and GLP-1R
TCGA database has comprehensive cancer genomic profiles,
including transcriptomic data of over 30 human tumours [32]. Our
bioinformaticist (MS) extracted publicly available mRNA expression
profiles of PSMA2 and GLP-1R generated from RNA-sequencing
experiments, and analysed their differences using Gene Expression
Profiling Interactive Analysis 2 [33]. We examined 13 types of cancer
including invasive breast carcinoma (BRCA), cervical squamous cell
carcinoma and endocervical adenocarcinoma (CESC), cholangiocarci-
noma (CHOL), colon adenocarcinoma (COAD), lymphoid neoplasm
diffuse large B-cell lymphoma (DLBC), oesophageal carcinoma
(ESCA), head and neck squamous cell carcinoma (HNSC), liver hepa-
tocellular carcinoma (LIHC), lung squamous cell carcinoma (LUSC),
pancreatic adenocarcinoma (PAAD), rectum adenocarcinoma (READ),
stomach adenocarcinoma (STAD), and thymoma (THYM). For each
type of cancer, the gene expression was matched with that in normal
samples in the Genotype-Tissue Expression (GTEx) database [34].2.2. Cell lines and treatment
We used cancer cell lines including human breast cancer cell line
MCF-7 (RRID: CVCL_0031), and non-cancerous cell lines including
mouse fibroblastic cell line L929 (RRID: CVCL_0462) and human
embryonic kidney cell line 293 (RRID: CVCL_0045) to conduct a series
of experiments. These cell lines were cultured in DMEM medium
(Cat. 11885076, Invitrogen, USA) with 10% FBS (Cat. 26140079, fetal
bovine serum) (Gibco, USA), and 1% Antibiotic-Antimycotic (Ampho-
tericin B, Penicillin, Streptomycin) (Cat. 15240112, Gibco, USA). We
included three human cervical cancer cell lines SiHa (RRID:
CVCL_0032), HeLa (RRID: CVCL_0030), and C33A (RRID: CVCL_1094),
which were cultured in MEM medium (Cat. 12571071, Invitrogen,
USA) with 10% FBS, and 1% Antibiotic-Antimycotic. These cell lines
have been validated by Department of Anatomical and Cellular
Pathology core laboratory at the CUHK using DNA fingerprinting.
Our group established CUP-1 by incorporating HPV-16 E7 and
activated EJ-ras oncogene into baby mouse kidney epithelial cells
from C57BL/KSJ mice, which shares the same genetic background of
db/db mice. We immortalized the cell line with stable expression of
HPV-16 E7 oncogene, which was inoculated in db/dbmice for tumour
development [30,31]. CUP-1 cells were cultured in DMEM medium(Cat. 11885076, Invitrogen, USA) with 10% FBS, and 1% Antibiotic-
Antimycotic.
The above cell lines underwent overnight serum starvation in
medium with normal glucose and low FBS (1%). The culture medium
was replaced with fresh medium with low (2.8mmol/L), normal
(5.5 mmol/L) or high glucose (25 mmol/L) for 48h for molecular anal-
ysis. CUP-1 cells were treated with Exendin-4 (Cat. E7144, Sigma-
Aldrich, US) at concentrations of 0, 5, 20, and 50 nmol/L for 6, 24, and
48 h. Cells for in vitro studies were passaged from one relevant cell
lines in the same condition with highly homogenous phenotypes. All
in vitro experiments were repeated at least twice with at least 3 sam-
ples in each experiment, hence results of 6 samples were analysed
and presented.
2.3. Human tissue
A case-control study were conducted to compare the RNA and
protein differences in PSMA2 and GLP-1R expression in cervical can-
cer specimens from patients with or without T2D. All specimens
were obtained during radical hysterectomy performed at the Prince
of Wales Hospital (PWH), the teaching hospital of the CUHK, between
January 2016 and July 2019. We retrieved frozen tissue and histologi-
cal samples of age-matched patients with or without T2D. Frozen
samples were used for RNA expression analysis and cut into 3-mm
sections for microdissection using a fine surgical blade to isolate
tumour-specific cells under an inverted microscope.
The medical records of these patients were reviewed using the
territory-wide electronic medical system shared by all publicly-
funded hospitals and clinics. Diabetes was defined based on physi-
cian-diagnosed T2D and/or prescription of glucose-lowering drugs
and/or abnormal laboratory values as defined by the American Diabe-
tes Association guidelines: HbA1c  6.5%, or fasting plasma glucose 
7.0 mmol/L, or 2-h plasma glucose  11.1 mmol/L during a 75 g oral
glucose tolerance test (OGTT), or random plasma glucose 
11.1 mmol/L with typical symptoms of hyperglycemia or hypergly-
caemic crisis.
2.4. Animal experiments, tumour induction, and oral glucose tolerance
test
10-week old male db/db mice (Jackson Stock #000642, BKS.Cg-
Dock7m+/+Leprdb /J) were obtained from the CUHK Laboratory Ani-
mal Services Centre and transferred to the Animal House of the Li Ka
Shing Institute of Health Sciences (LKS) based at the PWH. All mice
were housed in a temperature-controlled room (22 °C) on a 12-h
light-dark cycle with free access to food and water at the PWH.
To examine the cancer-promoting effect of PSMA2 and anti-can-
cer effect of Exendin-4, we inoculated db/db mice with the same
number (2 £ 107) of CUP-1 cells, psma2-shRNA transfected CUP-1
cells, or psma2-vector transfected CUP-1 cells subcutaneously under-
neath the nape of the neck (scruff). After inoculation (Day 0), the
mice were assigned to receive either a daily intraperitoneal injection
of Exendin-4 (30 nM/kg body weight) [31] or PBS for 13 days with
710 mice in each group.
On day 3, tumour developed at the scruff of the mice, and the size
was measured by calliper (Mitutoyo, Taiwan) twice weekly during
the treatment period. Tumour volumes were calculated using the
equation V= (a £ b2) £ 0.5236, where “a” was the larger dimension
and “b” the perpendicular diameter [35]. Bodyweight, food consump-
tion, and random blood glucose were also measured twice weekly
during the treatment period. None of the mice developed a tumour
larger than 2 £ 2 cm2 to meet the exclusion criteria.
On day 14, an oral glucose tolerance test (OGTT) was performed
after overnight fasting for 15 h to examine the anti-diabetic effects of
Exendin-4. For OGTT, the mice were gavaged with 20% glucose (1 g/
kg) after blood collection at baseline (0 min). All blood samples were
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measurements, followed by tumour collection for histological analy-
sis. Mice were sacrificed by inhalation of carbon dioxide provided by
the LKS Animal House based at the PWH.
2.5. Plasmid, shRNA, and siRNA transfection
For psma2 overexpression plasmid construction, mouse cDNA
encoding psma2 was amplified using the following primers: forward
(F) 5’- GAGCGCGGTTACAGCTTCT-3’, reverse (R) 5’- GCAGCTT-
TAATCCCCACTGAC-3’. The amplified fragment was sub-cloned into
pcDNA3.1+ vector between BamH1(5’) and XhoI (3’) restriction sites
and confirmed by sequencing analysis. The above plasmid DNA frag-
ment was sent to Hanbio (China) for lentiviral expression and pack-
aging.
For psma2 knockdown, shRNA lentivirus particles were purchased
from Sigma (Cat. SH0731, USA) and used according to the manufac-
turer’s instructions. Lentivirus overexpression (20 mL of 1 £ 106 viral
titre) or downregulation (200 mL of 1 £ 105 viral titre) particles were
added to the wells for transfection. After 12 h, the mediumwith lenti-
virus particles was replaced with fresh medium for incubation for
48h, followed by puromycin selection for at least 14 days. The surviv-
ing cells were examined for psma2 expression by RT-PCR and used as
cell lines with stable psma2 overexpression or downregulation for
molecular and animal studies.
For GLP-1R knockdown, siRNA was purchased from Invitrogen
(Cat. 4390771, USA) and used according to the manufacturer’s
instructions. 15 pmol siRNA particles together with lipofectamine
2000 (Cat. 11668027, Invitrogen, USA) were added to the wells for
transfection. After 12 h, the medium was replaced with fresh medium
for incubation for 48 h. Western blotting (WB) was performed to vali-
date GLP-1R downregulation.
2.6. MTT and cell proliferation assay
We seeded 10002000 cells into each well of 96-well plate for
overnight incubation. After treatment based on different experimen-
tal design, we added 10 mL MTT Reagent (Sigma-Aldrich, USA) into
the cell medium for incubation for 4 h until a purple precipitate was
visible. The cell medium was replaced with 100 mL DMSO for 2 h-
incubation in the dark, followed by an absorbance record at 570 nm.
3000 cells of each cell line were seeded in 96-well cell culture
plates for overnight incubation. After treatment based on different
experimental design, cell proliferation was analysed daily up to 72 h
by cell counting using a haemocytometer.
2.7. Histological staining
We used human cervical cancer histological samples from Depart-
ment of Anatomical and Cellular Pathology CUHK for PSMA2 and
GLP-1R immunofluorescence (IF) staining. Mice tumour was collected
after treatment and fixed in 4% (v/v) paraformaldehyde overnight
and embedded in paraffin. Sections were cut to 4 mm thickness for IF
staining of Ki67 and PSMA2.
For IF staining, after rehydration, slides were placed in 0.5% (v/v)
triton X for 20 min for permeabilization, followed by 0.01 mol/L
sodium citrate buffer (pH 6.0) and heated at ~100 °C for 10 min for
antigen retrieval. After blocking nonspecific antigens, rabbit anti-
Ki67, PSMA2, or GLP-1R antibody was applied to the sections over-
night at 4 °C. The sections were then washed in PBST three times and
incubated with fluorescence-conjugated secondary antibodies, Alexa
Fluor goat anti-rabbit 555 at room temperature (RT) for 1 h, fol-
lowed by counterstaining of the nucleus with DAPI. The images were
captured using the Leica Qwin image analysis software (Leica, Ger-
many). Table S1 lists the antibodies used in these experiments.Images of at least 10 vision fields were captured in each slide and
positive signals were quantified using Image J.
2.8. Real-time PCR and immunoblotting
We used Trizol (Invitrogen, USA) to extract total RNA in all cell
models, followed by reverse transcription to cDNA (Takara, Japan).
cDNA was applied to SYBR-Green Kit (Promega, USA) and then
Applied Biosystems 7900HT for quantitative RT-PCR analysis. Mouse
primers are shown in table S1.
Total proteins from cells were extracted using ice-cold cell lysis
buffer (Cat. #9803, Cell Signalling Technology, USA) supplemented
with protease inhibitor (Roche, Switzerland) and Na3VO4 and then
adjusted to the same concentration by loading buffer and denatured.
After gel electrophoresis, transfer and blocking, membranes were
incubated in the primary antibodies at 4 °C overnight. The primary
antibodies included PSMA2, GLP-1R, phospho-P65, P65, phospho-
IkB, IkB, and GAPDH. HRP-linked anti-rabbit and anti-mouse IgG
were used as secondary antibodies. Protein bands were developed by
Immobilon Western Chemiluminescent HRP Substrate (Millipore,
Billerica, MA, USA). Table S1 lists the antibodies used in these experi-
ments.
2.9. Statistical analysis
In TCGA data analysis, for each type of cancer, we used ANOVA to
compare expression profiles between cancerous and normal samples.
Statistical significance was defined as an absolute log2 fold change >
0.5 and a p-value < 0.001.
In animal experiments, we calculated the sample size to be 7 in
each group (28 in total) based on the mean and standard deviation
(SD) (mean§SD) of tumour volume in the Exendin-4 group (500§
110 mm2) and control group (700§120 mm2) in a pilot study (n = 3
in each group), to achieve 90% power with an alpha (p) value less
than 0.05. Mice were randomly assigned to treatment or control
group. Treatment and measurements were performed at the same
time daily and in a random order to minimise potential confounders.
The conduct of experiment, tumour size measurements, and data
analysis were performed by different investigators blinded to the
treatment group. Mice were excluded if the tumour volume exceeded
2 £ 2 cm2. All data are presented as mean§SD (95% CI) with individ-
ual data point shown in histograms. We plotted the data to confirm
their normal distribution. We used Student's t-test and two-way
ANOVA with Tukey’s post hoc test, as appropriate, to examine
between-group differences using Prism (GraphPad Prism 7, San
Diego, CA, USA) with significance defined as p < 0.05.
In the analysis of human cervical cancer specimens, we included
patients who underwent hysterectomy for cervical cancer at the
PWH in 20162019, who consented to donate their cancer speci-
mens for research. We excluded those with immunodeficiency or
active substance abuse and identified patients who met inclusion cri-
teria for T2D and selected control subjects matched by age. We per-
formed a pilot study with 3 samples in each group and calculated a
sample size of 9 in each group was required based on the mean§SD
of PSMA2 RNA expression in the non-T2D group (1§1.4) and T2D
group (3 § 1.5, fold change) to achieve a power of 0.8 with an alpha
(p) value less than 0.05. The experiments and data analysis were con-
ducted with the analyst blinded to the group assignment. We com-
pared PSMA2 and GLP-1R expression between the T2D and non-T2D
group and performed correlation analysis in each group. A p-value <
0.05 (2-tailed) was considered as statistically significant.
2.10. Ethics
The human study protocol was approved by the Joint CUHK-New
Territories East Cluster Clinical Research Ethics Committees (CREC
D. Mao et al. / EBioMedicine 65 (2021) 103242 5Ref. No.: 2018.457). All patients gave written informed consent for
research and publication purposes. The animal experimental protocol
was approved by the Animal Experimentation Ethics Committee of
CUHK (AEEC Ref. No.: 17-089-MIS). All animal procedures were com-
pliant with guidelines on animal use.
2.11. Role of the funding source
The funders had no role in experimental design, data collection,
data analyses, interpretation, or manuscript writing. We were not
paid to write this article by any company or agency. The correspond-
ing author had full access to all data in this study.
2.12. Results
1 Increased PSMA2 expression in 12 human cancer types and cer-
vical cancer specimens from patients with T2D, further con-
firmed in multiple cervical cancer cell lines.
We identified tumour-specific overexpression of PSMA2 in 12
types of cancer from TCGA database, compared with respective
normal tissues from the GTEX database. These included breast,
cervical, cholangial, colorectal, lymphoid, oesophageal, head and
neck, liver, lung, pancreatic, stomach, and thymus cancer
(Fig. 2a). Based on the statistically significant increase in PSMA2
expression in cervical cancer, and the emerging role of PSMA2 in
both cancer and diabetes [13,14,36], we examined PSMA2 expres-
sion in cervical cancer specimens from patients with or without
T2D, multiple human and mouse cervical cancer cell lines and
non-cancerous cell lines.
Fig. 1 lists the flowchart of participant selection for analysis of
PSMA2 expression in cervical cancer specimens. Table 2 lists the clin-
ical characteristics of the selected participants in this study. We
retrieved these subjects' specimens for IF staining and RT-PCR analy-
sis for PSMA2 expression. In Fig. 2b and c, patients with T2D had
higher PSMA2 protein expression than those without T2D (T2D:
0.59%, 95% CI: 0.470.72; Non-T2D: 0.36%, 95% CI: 0.250.46;
P = 0.004, t-test) (n = 9 in each group). In Fig. 2d, RT-PCR analysis
revealed a 3-fold increase in PSMA2 expression in patients with T2DFig. 1. Flowchart of participant selecti(T2D: 3.22 (fold change), 95% CI: 1.385.05; Non-T2D: 1.00, 95% CI:
0.661.34; P = 0.01, t-test).
To test the hypothesis of whether high glucose condition
would alter the expression of this potential proto-oncogene, we
determined the PSMA2 expression in multiple epithelial cervical
cancer cell lines. High glucose (25 mmol/L) increased PSMA2
expression in SiHa (P = 0.04, t-test), HeLa (P = 0.04, t-test), and
C33A cells (P = 0.04, t-test), but not in non-cancerous mouse
fibroblast and human embryonic kidney cells (Fig. 2e). In CUP-1
cells, exposure to high glucose also upregulated psma2 expression
in a glucose-dose-dependent manner (normal glucose (NG) vs
low glucose (LG): ~1.5 folds, P = 0.008, t-test; HG vs NG: ~1.5
folds, P = 0.04, t-test) (Fig. 2f).
2 Psma2-O/E and -shRNA increased and decreased cell proliferation
and tumour volume respectively under high glucose
environment
We treated CUP-1 cells with psma2-O/E or -shRNA under normal
or high glucose condition followed by cell viability and proliferation
assay. High glucose promoted cell proliferation in CUP-1 cells
(P = 0.001, t-test). Enforced psma2-O/E transfection also promoted
CUP-1 cell proliferation under normal (P = 0.002, t-test) and high glu-
cose conditions (P = 0.005, t-test) (Fig. 3a and b). Consistent with the
above results, psma2-shRNA reduced cell viability and proliferation
in normal and in high glucose conditions in vitro (Fig. 3c and d). The
RNA and protein expression of PSMA2 in the above conditions was
confirmed (Fig. 3e-h).
To determine the role of psma2 in the hyperglycaemic back-
ground in vivo, we inoculated CUP-1 cells, or psma2-shRNA trans-
fected CUP-1 cells into db/db mice to induce tumour
development. Mice inoculated with psma2-shRNA-CUP-1 cells had
smaller tumour volume, compared with vector control group
(P = 0.002, ANOVA test) (Fig. 3i and j). Tumour with psma2-
shRNA-CUP-1 cells had decreased Ki67 expression, indicative of
reduced tumour proliferation in vivo (PSMA2-shRNA vehicle:
0.26%, 95% CI: 0.090.42; vector control: 0.46%, 95% CI:
0.320.60; P = 0.028, t-test) (Fig. 3k and l). Downregulation of
psma2 did not alter blood glucose level in vivo, suggesting that
the anti-cancer effect was not glucose-mediated (SFig. 2ac).on for analysis of cervical cancer.
Fig. 2. Increased PSMA2 expression in 12 human cancer types and cervical cancer specimens from patients with T2D, further confirmed in multiple cervical cancer cell lines. PSMA2
expression was examined in 13 types of cancer in TCGA database (a). Representative images of PSMA2 expression in cervical cancer specimens from patients with and without T2D
(b) (red: PSMA2, blue: DAPI, magnification: £ 400. The white scale bar represents 25 mm). Relative quantification of PSMA2-positive cells (c). RNA expression of PSMA2 was mea-
sured in cervical cancer specimens from patients with and without T2D (d) human cervical cancer cell lines SiHa, HeLa, and C33A, and non-cancerous mouse fibroblast cells (L929)
as well as human embryonic kidney cells (293) (e), and CUP-1 cells (f) in low glucose, or normal glucose, or high glucose medium by RT-PCR. Data are presented as mean§SD with
individual data points in histograms. * p < 0.05, ** p < 0.01, *** p < 0.001. (For interpretation of the references to color in this figure legend, reader can refer to the web version of
this article.)
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We treated human and mouse (CUP-1) cervical cancer cell lines
with Exendin-4 to examine PSMA2 expression. We treated psma2-O/
E-CUP-1 cells and psma2-shRNA-CUP-1 cells with Exendin-4 under
normal or high glucose condition for cell viability and proliferation
assay. Under high glucose condition, Exendin-4 (50 nmol/L)
decreased PSMA2 expression in CUP-1 cells by 3-fold (P = 0.01, t-test,
Fig. 4a) and in SiHa (P = 0.01, t-test), HeLa (P < 0.001, t-test), andC33A (P = 0.04, t-test) cells (Fig. 4h). Exendin-4 did not alter psma2
expression and cell proliferation in psma2-shRNA-CUP-1 cells
(Fig. 4b-d). In psma2-O/E-CUP-1 cells, Exendin-4 reduced psma2
expression by 60% (P = 0.003, t-test) and cell viability and prolifera-
tion (P < 0.001, ANOVA) under high glucose condition (Fig. 4eg).
We inoculated CUP-1 cells into db/db mice to induce tumour
development with or without Exendin-4 treatment. Consistent with
the above in vitro findings, Exendin-4 treatment reduced the tumour
volume (P < 0.001, ANOVA test), starting from day 7 (Exendin-4 vs
vehicle control: 513.6 (95% CI: 408.4618.7) vs 749.9 (95% CI:
Fig. 3. Psma2-O/E and -shRNA increased and decreased cell proliferation and tumour volume respectively under high glucose environment Cell viability (a) and proliferation (b)
were measured in CUP-1 cells with and without psma2-O/E in normal or high glucose medium by MTT and cell counting. The upregulation of the RNA and protein expression of
psma2was confirmed after enforced overexpression by RT-PCR and WB (e, f). Cell viability (c) and proliferation (d) were measured in CUP-1 cells with and without psma2-shRNA in
normal or high glucose medium by MTT and WB. Downregulation of the RNA expression of psma2 was confirmed after psma2-shRNA transfection by RT-PCR and WB (g, h). (e-f)
Tumour volume was measured twice weekly after inoculation of CUP-1 cells with psma2-shRNA or vector into db/db mice (N = 7 in each group) (i, j). Cell proliferation marker Ki67
(k, l) was measured in the tumour of the above diabetes/cancer mice (red: Ki67, blue: DAPI, magnification: £ 200. The white scale bar represents 50 mm). Data are presented as
mean§SD with individual data points in histograms. * p < 0.05, ** p < 0.01, *** p < 0.001. (For interpretation of the references to color in this figure legend, reader can refer to the
web version of this article.)
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decreased Ki67 (Exendin-4: 0.27%, 95% CI: 0.070.47; vehicle con-
trol: 0.47%, 95% CI: 0.350.59; P = 0.04, t-test) (Fig. 4k and l) and
PSMA2 expression (Exendin-4: 0.39%, 95% CI: 0.230.55; vehicle con-
trol: 0.61%, 95% CI: 0.440.78; P = 0.03, t-test) in tumours, compared
with the vehicle-treated group (Fig. 4m and n).
4 In human cervical cancer specimen, GLP-1R expression was
increased and positively correlated with PSMA2 expression in
patients with T2D, supplemented by experimental evidence in
multiple cervical cancer systems.
To understand why Exendin-4 exerted the aforementioned
effects, we first examined the RNA expression of GLP-1R in 13 types
of cancer from TCGA database. There was no expression difference
between tumour tissues and respective normal tissues, although dia-
betes status in these patients was unknown (Fig. 5a). We then ana-
lysed the protein and RNA expression of GLP-1R in human cervical
cancer specimens and multiple cervical cancer cell lines. We found a
2-fold increase in GLP-1R protein expression (T2D: 0.39%, 95% CI:
0.300.48; Non-T2D: 0.21%, 95% CI: 0.130.30; P = 0.004, t-test)
(Fig. 5b and c) and a 5-fold increase in GLP-1R RNA expression in cer-
vical cancer specimens from patients with T2D, compared with those
without T2D (T2D: 5.49 (fold change), 95% CI: 3.007.98; Non-T2D:
1.00, 95% CI: 0.51.5; P = 0.003, t-test) (Fig. 5d). We performed corre-
lation analysis between PSMA2 and GLP-1R expression in the T2D
and non-T2D group separately. There was positive correlation in the
T2D (r = 0.68, 95% CI: 0.020.92, P = 0.046, correlation test) but not in
the non-T2D group (r = 0.29, 95% CI: 0.470.80, P = 0.46, correlation
test) (Fig. 5e and f).
High glucose increased RNA and protein expression of GLP-1R in
human and mouse cervical cancer cell lines (Fig. 5gh, im). In CUP-
1 cells, GLP-1R expression was increased in a glucose-dose-depen-
dent manner (NG vs LG: ~3 folds, P = 0.001, t-test; HG vs NG: ~3 folds,
P = 0.007, t-test) (Fig. 5h). Upon knockdown of GLP-1R, there wascorrespondingly reduced expression of PSMA2 under normal and
high glucose conditions (Fig. 5mo).
5 High glucose activated NF-kB signalling pathway but attenuated
by Exendin-4 in CUP-1 cells
We treated CUP-1 cells with or without Exendin-4 under normal
or high glucose condition to evaluate the protein expression of psma2
and NF-kB signalling inflammatory markers phospho-p65 and phos-
pho-IkB. High glucose increased psma2 protein expression (P = 0.02,
t-test), which was attenuated by Exendin-4 (P = 0.003, t-test) (Fig. 6a
and b). High glucose increased protein expression of phospho-p65
(P = 0.04, t-test) and phospho-IkB (P = 0.003, t-test), which were
attenuated by Exendin-4 (Fig. 6c and d).
3. Discussion
In this translational study, we have used human and experimental
studies to test the hypothesis regarding the roles of PSMA2 and GLP1-
RA in cervical cancer with data summarised in Table 1. We discov-
ered, PSMA2 and GLP-1R expression were increased and positively
correlated in cervical cancer specimens from patients with T2D.
Exendin-4 attenuated PSMA2 expression and tumour growth in vivo
and in vitro. In TCGA database, PSMA2 was over-expressed in 12
human cancer types. Experimentally, high glucose increased PSMA2
expression in multiple human and mouse epithelial cervical cancer
cell lines (CUP-1), the latter being glucose-dependent, but not in
non-cancerous cells. In the CUP-1 cells, psma2-O/E and psma2-shRNA
increased and decreased cell proliferation, respectively. In vivo,
psma2-shRNA attenuated tumour growth and cell proliferation. In
vitro, high glucose upregulated psma2 expression and cell prolifera-
tion in CUP-1 cells, which were exacerbated with psma2-O/E but
attenuated by Exendin-4. The latter also attenuated tumour growth,
cell proliferation and PSMA2 expression in vivo. There was no differ-
ence in GLP-1R expression in 12 cancer types in TCGA database, albeit
with unknown glycaemic status. GLP-1R expression was increased
Fig. 4. Exendin-4 reduced PSMA2 expression, cell proliferation, and tumour volume in vitro and in vivo. (a) The RNA expression of psma2 was measured in CUP-1 cells after treat-
ment with Exendin-4 at the concentration of 0, 5, 20, and 50 nmol/L for 48 h in normal or high glucose medium. (b-d) The RNA expression of psma2, cell viability, and proliferation
were examined in psma2-shRNA-CUP-1 cells with or without Exendin-4 treatment in normal or high glucose medium. (e-g) The RNA expression of psma2, cell viability, and prolifer-
ation were examined in psma2-O/E-CUP-1 cells with or without Exendin-4 treatment in normal or high glucose medium. (h) The RNA expression of psma2 was examined in SiHa,
HeLa, and C33A human cervical cancer cell lines with or without Exendin-4 treatment in normal or high glucose medium. (i-j) Tumour volume was measured twice weekly after
inoculation of CUP-1 cells with treatment of Exendin-4 (30 nmol/kg) or vehicle (PBS) (N = 7 in each group). Cell proliferation marker Ki67 (k-l) (red: Ki67, blue: DAPI,
magnification: £ 200. The white scale bar represents 50 mm) and PSMA2 expression (m-n) were measured in the tumour of above diabetes/cancer mice (red: PSMA2, blue: DAPI,
magnification: £ 400. The white scale bar represents 25 mm). Data are presented as mean§SD with individual data points in histograms. * p < 0.05, ** p < 0.01, *** p < 0.001. (For
interpretation of the references to color in this figure legend, reader can refer to the web version of this article.)
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from patients with T2D, which were further validated by GLP-1R
knockdown in CUP-1 cells. GLP-1R expression was increased in multi-
ple human cervical cancer cell lines under high glucose condition and
in CUP-1 cells in a glucose-dose-dependent manner. High glucose
upregulated protein expression of psma2, p-P65, and p-IkB but atten-
uated by Exendin-4. Taken together, our data support the promoting
effect of high glucose on GLP-1R and PSMA2 expression in cervical
cancer, which can be attenuated by Exendin-4.
In experimental studies of diabetes, high glucose impaired the
ubiquitin-proteasome system function to cause abnormal cardiovas-
cular-renal function and amyloid precipitation in islets [36]. High glu-
cose activated the hexosamine-polyol-dicarbonyl methylglyoxial
(MGO) pathways accompanied by decreased proteasome activity in
diabetic kidney disease models [37]. On the other hand, MG132, a
proteasome inhibitor, attenuated diabetic nephropathy by enhancing
renal antioxidative capacity and histone degradation [3840].
Increased proteasome expression was implicated in atherosclerosis
[41], while insulin deficiency activated proteasome activity and
caused cardiac muscle dysfunction [42]. However, these experimen-
tal results were not always consistent. In human studies, both
decreased and increased proteasome expression had been reported
in specimens from patients with T2D and cardiovascular disease [43].
In contrast, the upregulation of the ubiquitin-proteasome system had
been consistently reported in carcinogenesis [44]. This was supported
by the use of proteasome inhibitors as first-line adjunctive drugs in
addition to conventional chemotherapy in patients with multiple
myeloma to maximize efficacy and minimize treatment resistance
[45].
Proteasome alpha subunit has seven isoforms encoded by seven
genes PSMA1-7. In TCGA database, we noted increased PSMA2 expres-
sion in 12 human cancer types, including cervical epithelial cancer. In
vitro, we confirmed high glucose increased PSMA2 expression and
cell proliferation in cervical and breast cancer cell lines attenuated by
Exendin-4 (SFig. 1). This effect was corroborated by increased tumour
growth in the diabetes/cancer model. The proto-oncogenic role of
psma2 was confirmed by transfection studies where psma2-O/E
enhanced, and psma2-shRNA reduced cancer growth. In vivo, psma2-
shRNA did not alter blood glucose level, suggesting that this effect
was independent of glucose-lowering effect (SFig. 2). These experi-
mental results were corroborated by increased expression of PSMA2
in cervical cancer specimens from patients with T2D. These original
findings suggested that dysregulation of PSMA2 might underlie the
high risk of cancer in T2D. The glucose-dependent upregulation ofPSMA2 in breast cancer cells (SFig. 1a) and its increased expression in
multiple cancer types in TCGA database, along with the genetic asso-
ciations of PSMA2 SNPs with various cancer types [14,15] suggest
that the proto-oncogenic role of PSMA2 might apply to other cancer
cell types.
There are few studies which systemically examined the effects of
hyperglycaemia on cancer and the therapeutic effects of glucose low-
ering drugs on cancer. The mechanism of Exendin-4 on tumour atten-
uation was multifactorial. Previous evidence indicated that Exendin-4
attenuated prostate tumour growth by inhibiting extracellular phos-
phorylation in signal-regulated kinase (ERK)-mitogen-activated pro-
tein kinase (MAPK) pathway and inhibition of NF-kB activation
[23,46,47]. In our study, Exendin-4 reduced high-glucose-upregu-
lated PSMA2 expression, but not in normal glucose condition in cervi-
cal cancer cells. Different cancer types might exhibit different
behaviours with different dominant pathologies. Unlike prostate can-
cer, cervical cancer was mainly induced by HPV infection, and the
inflammation might be exaggerated by hyperglycaemia [48]. The
anti-inflammatory effect of Exendin-4 has been well reported
[27,49]. PSMA was involved in proinflammatory pathways and
whether the anti-cancer effect of Exendin-4 through PSMA reduction
was mediated by anti-inflammation required further elucidation.
Given the cross-talk between hyperglycaemia and inflammation [50],
our study provided new insights regarding the potential of using
Exendin-4 to treat cancer in patients with T2D.
The effect of hyperglycaemia on GLP-1R expression in cancer and
non-cancer tissues might be different. Chronic hyperglycaemia
decreased GLP-1R expression in pancreatic beta cells in diabetes,
which might contribute towards the impaired incretin and insulin
secretion [51]. In patients with obesity, decreased GLP-1R expression
had been reported in vascular endothelial cells [52]. By contrast,
increased expression of GLP-1R expression had been reported in vari-
ous types of human tumour, including endocrine tumours and lung
cancer [53,54]. According to the Warburg's hypothesis, cancer cells
exhibit high rates of glycolysis with lactic acid production, which
might require increased glucose uptake [55,56]. Taken together, we
hypothesized that in cancer cells, hyperglycemia might increase GLP-
1R expression to promote glucose uptake to fuel cell growth.
In support of this hypothesis, we demonstrated that high glucose
increased GLP-1R expression in human and mouse epithelial cervical
cancer cell lines. These findings were corroborated by increased
expression of PSMA2 and GLP-1R and their positive correlations in
cervical cancer specimens only from patients with T2D. The cross-
talk between GLP-1R and PSMA2 pathways in carcinogenesis was
Fig. 5. In human cervical cancer specimen, GLP-1R expression was increased and positively correlated with PSMA2 expression in patients with T2D, supplemented by experimental
evidence in multiple cervical cancer systems. GLP-1R expression was examined in TCGA database (a). The protein (b, c) (red: GLP-1R, blue: DAPI, magnification: £ 400. The white
scale bar represents 25 mm) and RNA expression (d) of GLP-1R was examined in cervical cancer specimens from patients with and without T2D. (e-f) Correlation analysis was per-
formed between GLP-1R and PSMA2 expression in cervical cancer specimens from patients with and without T2D. The RNA expression of GLP-1R was examined in human cervical
cancer cell lines (g) and CUP-1 cells (h). GLP-1R protein expression was examined in human cervical cancer cell lines under normal and high glucose medium (i-l). GLP-1R and
PSMA2 protein expression in CUP-1 cells with or without GLP-1R siRNA transfection (m-o). Data are presented as mean§SD with individual data points in histograms. * p < 0.05, **
p < 0.01, *** p < 0.001. (For interpretation of the references to color in this figure legend, reader can refer to the web version of this article.)
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12 D. Mao et al. / EBioMedicine 65 (2021) 103242plausible. Proteasome inhibitor attenuated widespread inflammation
by inhibiting the NF-kB pathway [57]. Proteasome could degrade IkB
and liberated the inflammatory signal of P65 to activate subsequent
nuclear transcription of inflammatory genes [58]. Other researchers
had reported the anti-inflammatory effects of Exendin-4 on macro-
phage migration in vitro as well as on breast cancer growth [59,60].
In our study, Exendin-4 attenuated phosphorylation of the P65 and
IkB in the NF-kB pathway, but the molecular mechanism underlying
this inhibitory effect required further elucidation.
There are limitations in this study. More experiments are needed
to elucidate the mechanism underlying the inhibitory effects ofFig. 6. High glucose activated NF-kB signalling pathway but attenuated by Exendin-4 in CU
mean§SD with individual data points in histograms. * p < 0.05, ** p < 0.01, *** p < 0.001.Exendin-4 on PSMA2 expression. The mechanisms underlying the
activation of proteasome in cancer development is complex, includ-
ing but not limited to chaperone protein overexpression, catalytic
subunits downregulation, upstream enzymes and transcription factor
activation [61]. The IKK inhibitor, a key blocker of the NF-kB pathway,
can be used to determine whether the cancer-promoting effects of
high glucose through psma2 expression is mediated by the NF-kB
pathway activation, which is known to promote inflammation and
tumour growth [62]. We are currently designing a series of experi-
ments to explore the molecular mechanisms underlying the cross-
talk between PSMA2 and GLP-1R, which is beyond the scope of thisP-1 cells. (a-d) Quantitative data was calculated in each group. Data are presented as
Table 1
Outcome measures in various experimental models.
": increase; #: decrease; (-): no change; T2D: type 2 diabetes; Exe-4: exendin-4; TCGA: the Cancer Genome Atlas Program; HG: high glucose; O/E: overexpression. Data are











Clinical characteristics of patients with cervical cancer selected for analysis.
Case No. Age (Y) Ethnicity Date of Operation
(dd/mm/year)
T2D HbA1c (%)
C1208 58 Chinese 22/12/2017 Yes 11.9
C1191 84 Chinese 04/08/2017 Yes 6.8
C1180 57 Chinese 19/04/2017 Yes 7.6
C1083 50 Chinese 15/09/2014 Yes 6.5
C1177 57 Chinese 19/04/2017 Yes 7.6
C1137 41 Chinese 18/01/2016 Yes 7.5
C1213 40 Chinese 18/01/2019 Yes 6.9
C1234 54 Chinese 29/04/2019 Yes 9.4
C1219 51 Chinese 09/02/2018 Yes Nil*
C1195 84 Chinese 17/08/2017 No 5.5
C1203 37 Chinese 22/11/2017 No 5.1
C1210 51 Chinese 05/01/2018 No Nil
C1220 59 Chinese 22/03/2018 No Nil
C1228 61 Chinese 18/05/2018 No Nil
C1229 56 Chinese 08/06/2018 No Nil
C1157 47 Chinese 22/08/2016 No Nil
C1185 70 Chinese 17/05/2017 No Nil
C1182 38 Chinese 24/04/2017 No Nil
*documented physician-diagnosed T2D.
14 D. Mao et al. / EBioMedicine 65 (2021) 103242paper. In our in vivo studies, we had only measured tumour volume.
Although it is preferable to measure both tumour weight and tumour
volume, the latter had been reported as the only measurement by
other workers [63]. The case-control clinical study was subject to
selection bias since only samples from Chinese women were
included. We did not adjust for confounding factors such as treat-
ment or other risk factors. Further studies in other ethnic groups will
be required to validate these observations. However, the increased
expression of PSMA2 and GLP-1R and their positive correlation in
patients with T2D concorded with the results from our experimental
studies.
In sum, our consistent results allow us to conclude that high glu-
cose increased PSMA2 expression and promoted tumour growth,
which could be attenuated by Exendin-4. The latter effects might be
mediated by reducing psma2 and NF-kB pathway activity. Since pro-
teasome inhibitors and GLP-1 mimetics are in clinical use, our data
have strong translational potential, especially in patients with T2D
and cancer, which co-expressed PSMA2 and GLP-1R. In these patients,
the anti-cancer effect of Exendin-4 should be explored in clinical tri-
als.
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